ABBOTT LABORATORIES Selling, General and Administrative Expense
ABBOTT LABORATORIES (ABT) reported Selling, General and Administrative Expense of $3.74 billion for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-04-29
- ABBOTT LABORATORIES selling, general and administrative expense for the quarter ending 2026-03-31 was $3.74B, a 22.18% increase year-over-year.
- ABBOTT LABORATORIES selling, general and administrative expense for the quarter ending 2025-12-31 was $3.13B, a 7.64% increase year-over-year.
- ABBOTT LABORATORIES selling, general and administrative expense for the quarter ending 2025-09-30 was $3.05B, a 5.39% increase year-over-year.
- ABBOTT LABORATORIES selling, general and administrative expense for the quarter ending 2025-06-30 was $3.09B, a 5.28% increase year-over-year.
- ABBOTT LABORATORIES selling, general and administrative expense for fiscal 2025 was $12.33B, a 5.43% increase from fiscal 2024.
- ABBOTT LABORATORIES selling, general and administrative expense for fiscal 2024 was $11.70B, a 6.83% increase from fiscal 2023.
- ABBOTT LABORATORIES selling, general and administrative expense for fiscal 2023 was $10.95B, a 2.66% decline from fiscal 2022.
- ABBOTT LABORATORIES selling, general and administrative expense for fiscal 2022 was $11.25B, a 0.67% decline from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | $3.74B 10-Q · filed 2026-04-29 | $6.87B derived: sum of 2 quarters · filed 2026-04-29 | $9.92B derived: sum of 3 quarters · filed 2026-04-29 | $13.01B derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2025-12-31 | $3.13B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $6.18B derived: sum of 2 quarters · filed 2026-02-20 | $9.27B derived: sum of 3 quarters · filed 2026-02-20 | $12.33B 10-K · filed 2026-02-20 | ||||
| 2025-09-30 | $3.05B 10-Q · filed 2025-10-29 | $6.14B derived: sum of 2 quarters · filed 2025-10-29 | $9.20B 10-Q · filed 2025-10-29 | $12.11B derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2025-06-30 | $3.09B 10-Q · filed 2025-07-30 | $6.15B 10-Q · filed 2025-07-30 | $9.06B derived: sum of 3 quarters · filed 2026-04-29 | $11.95B derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2025-03-31 | $3.06B 10-Q · filed 2026-04-29 | $5.97B derived: sum of 2 quarters · filed 2026-04-29 | $8.86B derived: sum of 3 quarters · filed 2026-04-29 | $11.80B derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2024-12-31 | $2.91B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $5.80B derived: sum of 2 quarters · filed 2026-02-20 | $8.74B derived: sum of 3 quarters · filed 2026-02-20 | $11.70B 10-K · filed 2026-02-20 | ||||
| 2024-09-30 | $2.90B 10-Q · filed 2025-10-29 | $5.83B derived: sum of 2 quarters · filed 2025-10-29 | $8.79B 10-Q · filed 2025-10-29 | $11.51B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-06-30 | $2.94B 10-Q · filed 2025-07-30 | $5.89B 10-Q · filed 2025-07-30 | $8.62B derived: sum of 3 quarters · filed 2026-02-20 | $11.34B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-03-31 | $2.96B 10-Q · filed 2025-04-30 | $5.68B derived: sum of 2 quarters · filed 2026-02-20 | $8.41B derived: sum of 3 quarters · filed 2026-02-20 | $11.15B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2023-12-31 | $2.72B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $5.45B derived: sum of 2 quarters · filed 2026-02-20 | $8.19B derived: sum of 3 quarters · filed 2026-02-20 | $10.95B 10-K · filed 2026-02-20 | ||||
| 2023-09-30 | $2.72B 10-Q · filed 2024-10-31 | $5.46B derived: sum of 2 quarters · filed 2024-10-31 | $8.22B 10-Q · filed 2024-10-31 | $11.20B derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-06-30 | $2.74B 10-Q · filed 2024-07-31 | $5.50B 10-Q · filed 2024-07-31 | $8.47B derived: sum of 3 quarters · filed 2025-02-21 | $11.21B derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-03-31 | $2.76B 10-Q · filed 2024-05-02 | $5.74B derived: sum of 2 quarters · filed 2025-02-21 | $8.47B derived: sum of 3 quarters · filed 2025-02-21 | $11.22B derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2022-12-31 | $2.97B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $5.70B derived: sum of 2 quarters · filed 2025-02-21 | $8.46B derived: sum of 3 quarters · filed 2025-02-21 | $11.25B 10-K · filed 2025-02-21 | ||||
| 2022-09-30 | $2.73B 10-Q · filed 2023-11-01 | $5.49B derived: sum of 2 quarters · filed 2023-11-01 | $8.28B 10-Q · filed 2023-11-01 | $11.32B derived: sum of 4 quarters · filed 2024-02-16 | ||||
| 2022-06-30 | $2.76B 10-Q · filed 2023-08-03 | $5.54B 10-Q · filed 2023-08-03 | $8.59B derived: sum of 3 quarters · filed 2024-02-16 | $11.36B derived: sum of 4 quarters · filed 2024-02-16 | ||||
| 2022-03-31 | $2.79B 10-Q · filed 2023-05-04 | $5.83B derived: sum of 2 quarters · filed 2024-02-16 | $8.60B derived: sum of 3 quarters · filed 2024-02-16 | $11.33B derived: sum of 4 quarters · filed 2024-02-16 | ||||
| 2021-12-31 | $3.05B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-16 | $5.82B derived: sum of 2 quarters · filed 2024-02-16 | $8.54B derived: sum of 3 quarters · filed 2024-02-16 | $11.32B 10-K · filed 2024-02-16 | ||||
| 2021-09-30 | $2.77B 10-Q · filed 2022-11-01 | $5.49B derived: sum of 2 quarters · filed 2022-11-01 | $8.28B 10-Q · filed 2022-11-01 | $10.85B derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2021-06-30 | $2.73B 10-Q · filed 2022-08-02 | $5.51B 10-Q · filed 2022-08-02 | $8.08B derived: sum of 3 quarters · filed 2023-02-17 | $10.38B derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2021-03-31 | $2.78B 10-Q · filed 2022-05-03 | $5.35B derived: sum of 2 quarters · filed 2023-02-17 | $7.66B derived: sum of 3 quarters · filed 2023-02-17 | $9.93B derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2020-12-31 | $2.57B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $4.87B derived: sum of 2 quarters · filed 2023-02-17 | $7.15B derived: sum of 3 quarters · filed 2023-02-17 | $9.70B 10-K · filed 2023-02-17 | ||||
| 2020-09-30 | $2.30B 10-Q · filed 2021-11-03 | $4.58B derived: sum of 2 quarters · filed 2021-11-03 | $7.13B 10-Q · filed 2021-11-03 | $9.54B derived: sum of 4 quarters · filed 2022-02-18 | ||||
| 2020-06-30 | $2.28B 10-Q · filed 2021-08-04 | $4.82B 10-Q · filed 2021-08-04 | $7.24B derived: sum of 3 quarters · filed 2022-02-18 | $9.68B derived: sum of 4 quarters · filed 2022-02-18 | ||||
| 2020-03-31 | $2.55B 10-Q · filed 2021-05-05 | $4.96B derived: sum of 2 quarters · filed 2022-02-18 | $7.40B derived: sum of 3 quarters · filed 2022-02-18 | $9.84B derived: sum of 4 quarters · filed 2022-02-18 | ||||
| 2019-12-31 | $2.41B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $4.85B derived: sum of 2 quarters · filed 2022-02-18 | $7.29B derived: sum of 3 quarters · filed 2022-02-18 | $9.77B 10-K · filed 2022-02-18 | ||||
| 2019-09-30 | $2.44B 10-Q · filed 2020-11-04 | $4.87B derived: sum of 2 quarters · filed 2020-11-04 | $7.35B 10-Q · filed 2020-11-04 | $9.71B derived: sum of 4 quarters · filed 2021-02-19 | ||||
| 2019-06-30 | $2.43B 10-Q · filed 2020-07-29 | $4.91B 10-Q · filed 2020-07-29 | $7.27B derived: sum of 3 quarters · filed 2021-02-19 | $9.65B derived: sum of 4 quarters · filed 2021-02-19 | ||||
| 2019-03-31 | $2.48B 10-Q · filed 2020-04-29 | $4.84B derived: sum of 2 quarters · filed 2021-02-19 | $7.21B derived: sum of 3 quarters · filed 2021-02-19 | $9.68B derived: sum of 4 quarters · filed 2021-02-19 | ||||
| 2018-12-31 | $2.36B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | $4.74B derived: sum of 2 quarters · filed 2021-02-19 | $7.20B derived: sum of 3 quarters · filed 2021-02-19 | $9.74B 10-K · filed 2021-02-19 | ||||
| 2018-09-30 | $2.38B 10-Q · filed 2019-10-31 | $4.84B derived: sum of 2 quarters · filed 2019-10-31 | $7.38B 10-Q · filed 2019-10-31 | $9.86B derived: sum of 4 quarters · filed 2020-02-21 | ||||
| 2018-06-30 | $2.47B 10-Q · filed 2019-07-31 | $5.01B 10-Q · filed 2019-07-31 | $7.49B derived: sum of 3 quarters · filed 2020-02-21 | $9.60B derived: sum of 4 quarters · filed 2020-02-21 | ||||
| 2018-03-31 | $2.54B 10-Q · filed 2019-05-01 | $5.02B derived: sum of 2 quarters · filed 2020-02-21 | $7.13B derived: sum of 3 quarters · filed 2020-02-21 | $9.28B derived: sum of 4 quarters · filed 2020-02-21 | ||||
| 2017-12-31 | $2.48B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $4.59B derived: sum of 2 quarters · filed 2020-02-21 | $6.74B derived: sum of 3 quarters · filed 2020-02-21 | $9.18B 10-K · filed 2020-02-21 | $9.12B 10-K · filed 2018-02-16 | |||
| 2017-09-30 | $2.12B 10-Q · filed 2018-10-31 | $2.10B 10-Q · filed 2017-11-02 | $4.26B derived: sum of 2 quarters · filed 2018-10-31 | $6.71B 10-Q · filed 2018-10-31 | $6.66B 10-Q · filed 2017-11-02 | $8.38B derived: sum of 4 quarters · filed 2019-02-22 | ||
| 2017-06-30 | $2.15B 10-Q · filed 2018-08-01 | $2.13B 10-Q · filed 2017-08-02 | $4.59B 10-Q · filed 2018-08-01 | $4.56B 10-Q · filed 2017-08-02 | $6.26B derived: sum of 3 quarters · filed 2019-02-22 | $7.89B derived: sum of 4 quarters · filed 2019-02-22 | ||
| 2017-03-31 | $2.44B 10-Q · filed 2018-05-02 | $2.42B 10-Q · filed 2017-05-03 | $4.11B derived: sum of 2 quarters · filed 2019-02-22 | $5.74B derived: sum of 3 quarters · filed 2019-02-22 | $7.48B derived: sum of 4 quarters · filed 2019-02-22 | |||
| 2016-12-31 | $1.67B derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $3.30B derived: sum of 2 quarters · filed 2019-02-22 | $5.04B derived: sum of 3 quarters · filed 2019-02-22 | $6.74B 10-K · filed 2019-02-22 | $6.67B 10-K · filed 2017-02-17 | |||
| 2016-09-30 | $1.63B 10-Q · filed 2017-11-02 | $3.37B derived: sum of 2 quarters · filed 2017-11-02 | $5.06B 10-Q · filed 2017-11-02 | $6.72B derived: sum of 4 quarters · filed 2018-02-16 | ||||
| 2016-06-30 | $1.74B 10-Q · filed 2017-08-02 | $3.44B 10-Q · filed 2017-08-02 | $5.09B derived: sum of 3 quarters · filed 2018-02-16 | $6.76B derived: sum of 4 quarters · filed 2018-02-16 | ||||
| 2016-03-31 | $1.70B 10-Q · filed 2017-05-03 | $3.35B derived: sum of 2 quarters · filed 2018-02-16 | $5.02B derived: sum of 3 quarters · filed 2018-02-16 | $6.75B derived: sum of 4 quarters · filed 2018-02-16 | ||||
| 2015-12-31 | $1.66B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $3.32B derived: sum of 2 quarters · filed 2018-02-16 | $5.05B derived: sum of 3 quarters · filed 2018-02-16 | $6.79B 10-K · filed 2018-02-16 | ||||
| 2015-09-30 | $1.67B 10-Q · filed 2016-11-03 | $3.39B derived: sum of 2 quarters · filed 2016-11-03 | $5.13B 10-Q · filed 2016-11-03 | $6.80B derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2015-06-30 | $1.73B 10-Q · filed 2016-08-03 | $3.46B 10-Q · filed 2016-08-03 | $5.13B derived: sum of 3 quarters · filed 2017-02-17 | $6.72B derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2015-03-31 | $1.74B 10-Q · filed 2016-05-04 | $3.40B derived: sum of 2 quarters · filed 2017-02-17 | $5.00B derived: sum of 3 quarters · filed 2017-02-17 | $6.65B derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2014-12-31 | $1.67B derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $3.26B derived: sum of 2 quarters · filed 2017-02-17 | $4.91B derived: sum of 3 quarters · filed 2017-02-17 | $6.53B 10-K · filed 2017-02-17 | ||||
| 2014-09-30 | $1.59B 10-Q · filed 2015-11-05 | $1.60B 10-Q · filed 2014-11-06 | $3.24B derived: sum of 2 quarters · filed 2015-11-05 | $4.86B 10-Q · filed 2015-11-05 | $4.89B 10-Q · filed 2014-11-06 | $6.41B derived: sum of 4 quarters · filed 2016-02-19 | ||
| 2014-06-30 | $1.65B 10-Q · filed 2015-08-04 | $1.79B 10-Q · filed 2014-08-05 | $3.27B 10-Q · filed 2015-08-04 | $3.55B 10-Q · filed 2014-08-05 | $4.81B derived: sum of 3 quarters · filed 2016-02-19 | $6.42B derived: sum of 4 quarters · filed 2016-02-19 | ||
| 2014-03-31 | $1.62B 10-Q · filed 2015-05-06 | $1.76B 10-Q · filed 2014-05-07 | $3.16B derived: sum of 2 quarters · filed 2016-02-19 | $4.77B derived: sum of 3 quarters · filed 2016-02-19 | $6.49B derived: sum of 4 quarters · filed 2016-02-19 | |||
| 2013-12-31 | $1.54B derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | $3.15B derived: sum of 2 quarters · filed 2016-02-19 | $4.87B derived: sum of 3 quarters · filed 2016-02-19 | $6.37B 10-K · filed 2016-02-19 | $6.94B 10-K · filed 2014-02-21 | |||
| 2013-09-30 | $1.61B 10-Q · filed 2014-11-06 | $1.73B 10-Q · filed 2013-11-07 | $3.33B derived: sum of 2 quarters · filed 2014-11-06 | $4.83B 10-Q · filed 2014-11-06 | $5.23B 10-Q · filed 2013-11-07 | $6.27B derived: sum of 4 quarters · filed 2015-02-27 | ||
| 2013-06-30 | $1.71B 10-Q · filed 2014-08-05 | $1.71B 10-Q · filed 2013-08-06 | $3.50B 10-Q · filed 2014-08-05 | $3.50B 10-Q · filed 2013-08-06 | $4.66B derived: sum of 3 quarters · filed 2015-02-27 | $6.58B derived: sum of 4 quarters · filed 2015-02-27 | ||
| 2013-03-31 | $1.79B 10-Q · filed 2014-05-07 | $1.79B 10-Q · filed 2013-05-08 | $2.94B derived: sum of 2 quarters · filed 2015-02-27 | $4.86B derived: sum of 3 quarters · filed 2015-02-27 | $6.68B derived: sum of 4 quarters · filed 2015-02-27 | |||
| 2012-12-31 | $1.16B derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $3.08B derived: sum of 2 quarters · filed 2015-02-27 | $4.89B derived: sum of 3 quarters · filed 2015-02-27 | $6.74B 10-K · filed 2015-02-27 | $12.06B 10-K · filed 2013-02-15 | |||
| 2012-09-30 | $1.92B 10-Q · filed 2013-11-07 | $2.92B 10-Q · filed 2012-11-07 | $3.73B derived: sum of 2 quarters · filed 2013-11-07 | $5.58B 10-Q · filed 2013-11-07 | $8.87B 10-Q · filed 2012-11-07 | $3.09B derived: sum of 4 quarters · filed 2014-02-21 | ||
| 2012-06-30 | $1.81B 10-Q · filed 2013-08-06 | $2.94B 10-Q · filed 2012-08-07 | $3.66B 10-Q · filed 2013-08-06 | $5.94B 10-Q · filed 2012-08-07 | $1.17B derived: sum of 3 quarters · filed 2014-02-21 | $5.41B derived: sum of 4 quarters · filed 2014-02-21 | ||
| 2012-03-31 | $1.84B 10-Q · filed 2013-05-08 | $3.00B 10-Q · filed 2012-05-08 | -$644.28M derived: sum of 2 quarters · filed 2014-02-21 | $3.59B derived: sum of 3 quarters · filed 2014-02-21 | $6.36B derived: sum of 4 quarters · filed 2014-02-21 | |||
| 2011-12-31 | -$2.49B derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-21 | $1.75B derived: sum of 2 quarters · filed 2014-02-21 | $4.51B derived: sum of 3 quarters · filed 2014-02-21 | $7.37B 10-K · filed 2014-02-21 | $12.76B 10-K · filed 2012-02-21 | |||
| 2011-09-30 | $4.24B 10-Q · filed 2012-11-07 | $7.00B derived: sum of 2 quarters · filed 2012-11-07 | $9.85B 10-Q · filed 2012-11-07 | $12.65B derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2011-06-30 | $2.76B 10-Q · filed 2012-08-07 | $5.61B 10-Q · filed 2012-08-07 | $8.41B derived: sum of 3 quarters · filed 2013-02-15 | $11.08B derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2011-03-31 | $2.85B 10-Q · filed 2012-05-08 | $5.65B derived: sum of 2 quarters · filed 2013-02-15 | $8.32B derived: sum of 3 quarters · filed 2013-02-15 | $11.06B derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2010-12-31 | $2.80B derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $5.47B derived: sum of 2 quarters · filed 2013-02-15 | $8.21B derived: sum of 3 quarters · filed 2013-02-15 | $10.38B 10-K · filed 2013-02-15 | ||||
| 2010-09-30 | $2.67B 10-Q · filed 2011-11-04 | $5.42B derived: sum of 2 quarters · filed 2011-11-04 | $7.58B 10-Q · filed 2011-11-04 | $9.80B derived: sum of 4 quarters · filed 2012-02-21 | ||||
| 2010-06-30 | $2.74B 10-Q · filed 2011-08-04 | $4.91B 10-Q · filed 2011-08-04 | $7.13B derived: sum of 3 quarters · filed 2012-02-21 | $9.22B derived: sum of 4 quarters · filed 2012-02-21 | ||||
| 2010-03-31 | $2.16B 10-Q · filed 2011-05-06 | $4.39B derived: sum of 2 quarters · filed 2012-02-21 | $6.47B derived: sum of 3 quarters · filed 2012-02-21 | $8.50B derived: sum of 4 quarters · filed 2012-02-21 | ||||
| 2009-12-31 | $2.23B derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-21 | $4.31B derived: sum of 2 quarters · filed 2012-02-21 | $6.33B derived: sum of 3 quarters · filed 2012-02-21 | $8.41B 10-K · filed 2012-02-21 | ||||
| 2009-09-30 | $2.09B 10-Q · filed 2010-11-05 | $4.11B derived: sum of 2 quarters · filed 2010-11-05 | $6.18B 10-Q · filed 2010-11-05 | $8.48B derived: sum of 4 quarters · filed 2011-02-18 | ||||
| 2009-06-30 | $2.02B 10-Q · filed 2010-08-05 | $4.10B 10-Q · filed 2010-08-05 | $6.39B derived: sum of 3 quarters · filed 2011-02-18 | $8.46B derived: sum of 4 quarters · filed 2011-02-18 | ||||
| 2009-03-31 | $2.07B 10-Q · filed 2010-05-04 | $4.37B derived: sum of 2 quarters · filed 2011-02-18 | $6.44B derived: sum of 3 quarters · filed 2011-02-18 | $8.49B derived: sum of 4 quarters · filed 2011-02-18 | ||||
| 2008-12-31 | $2.30B derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-18 | $4.37B derived: sum of 2 quarters · filed 2011-02-18 | $6.42B derived: sum of 3 quarters · filed 2011-02-18 | $8.44B 10-K · filed 2011-02-18 | ||||
| 2008-09-30 | $2.07B 10-Q · filed 2009-11-06 | $4.12B derived: sum of 2 quarters · filed 2009-11-06 | $6.14B 10-Q · filed 2009-11-06 | |||||
| 2008-06-30 | $2.05B 10-Q · filed 2009-08-07 | $4.07B 10-Q · filed 2009-08-07 | ||||||
| 2007-12-31 | $7.41B 10-K · filed 2010-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |